Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

ract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease and is administered by intramuscular injection. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestation age), and children with hemodynamically significant CHD. Synagis has been used in more than one million children in the U.S. since its introduction in 1998. The first dose of Synagis should be administered prior to commencement of the RSV season. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Very rare cases (<1 per 100,000 patients) of anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. Cases of anaphylaxis were reported following re-exposure to Synagis and rare severe hypersensitivity reactions occurred on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reaction occurs, caution should be used on re-administration of Synagis.

In clinical trials, the most common adverse events occurring at least 1 percent more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever and rhinitis. Cyanosis and arrhythmia were seen in children with CHD.

For full prescribing information for Synagis, see the company's website at: www.medimmune.com/products/synagis/index.asp.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the ar
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
... a clinico-molecular informatics company, today announced the commercialization ... lines that translate patient-specific molecular and genomic data, ... more effective drug choices for patients. ... drastically and clinical data becoming increasingly accessible, today,s ...
... /PR Newswire-Asia/ -- Global Pharm Holdings Group, Inc. ... growing vertically integrated pharmaceutical company engaged in the ... processing, and herbal cultivation and sales in China ... Shandong provinces, today announced the appointment of Mr. ...
Cached Medicine Technology:MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:7/21/2014)... PowerObjects, a professional services firm ... add-ons for Microsoft Dynamics CRM, has joined the ... group of the most strategic Microsoft Dynamics partners ... rank them in the highest echelon of the ... the Microsoft Dynamics Inner Circle have performed to ...
(Date:7/21/2014)... have a clot in their legs and are ... medication or undergo a minimally-invasive catheter-based clot removal ... difference in death rates between the two treatments, ... catheter procedure, according to a study by Temple ... a review of more than 90,000 cases nationwide., ...
(Date:7/21/2014)... The "viral reservoir" in which HIV can lie dormant ... earlier than previously thought, new animal research indicates. ... eradicate the AIDS-causing virus, said Harvard researchers working with ... presence of the viral reservoir remains the most significant ... HIV, known as HIV-1. "We found that the ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Western ... “Great College to Work For” by the Chronicle ... and also made the Honor Roll for the ... categories: Collaborative Governance, Compensation and Benefits, Confidence in ... Respect & Appreciation. , “Western University of Health ...
(Date:7/21/2014)... A new study suggests that potential help in lowering ... refrigerator. The study found that regular intake of ... supplements, may help ease the condition. Researchers looked ... probiotics and blood pressure. The studies involved a total ... pressure. People who consumed probiotics had an average ...
Breaking Medicine News(10 mins):Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
... nearly 8,800 women with early-stage breast cancer found that ... their full regimen of hormone therapy according to the ... likely to discontinue treatment. The findings underscore the need ... non-compliance and also develop interventions to reduce it. ...
... ... at Buffalo, led by the Department of Neurosurgery, will embark on a landmark ... therapy—dubbed “liberation treatment”—on MS symptoms and progression. , ... (Vocus) June 28, 2010 -- Recently, ...
... transition stage between the cognitive decline of normal aging ... But what leads to mild cognitive impairment? Researchers ... though not necessarily impaired, performance on tests measuring story ... dependent on visual control, as well as symptoms of ...
... ... energy bars at elementendurance.com. , ... Chicago, IL (PRWEB) June 28, 2010 -- Element Bars, the company that pioneered customized energy ... bars to their training and race needs. , , , , ,Here in our hometown ...
... LEXINGTON, Ky. (June 28, 2010) − Scientists at the ... in the brains of normal individuals at high risk ... detection of the disease. The research, led by ... on the brain,s white matter, which forms the majority ...
... 28, 2010 A nose job to treat a ... anxiety disorder? These are just two procedures that people ... in order to deal with body-related concerns. The excessive ... obsessive rituals and social isolation, is what scientists from ...
Cached Medicine News:Health News:Fewer than half of breast cancer patients adhere to hormonal therapy regimen, study finds 2Health News:Fewer than half of breast cancer patients adhere to hormonal therapy regimen, study finds 3Health News:Clinical Trial Testing New Multiple Sclerosis Treatment to Launch in Buffalo 2Health News:Clinical Trial Testing New Multiple Sclerosis Treatment to Launch in Buffalo 3Health News:Memory problems not the only predictor of later mild cognitive impairment 2Health News:Element Endurance &#8211; Custom Energy Bars for Athletes 2Health News:Alzheimer's imaging study identifies changes in brain's white matter 2Health News:New therapy to overcome body dysmorphic disorder 2Health News:New therapy to overcome body dysmorphic disorder 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: